生物类与靶向合成改善病情抗风湿药研究进展  

Research Progress of the Biological Disease Modifying Anti-rheumatic Drugs and Targeted Synthetic Disease Modifying Anti-rheumatic Drugs

作　　者：林晨 侯欢 彭铖 闫珊乐 陈蓉[1] LIN Chen;HOU Huan;PENG Cheng;YAN Shanle;CHEN Rong(Department of Pharmacy,the First Affiliated Hospital of Soochow University,Suzhou 215031,China;Suzhou Industrial Park Food and Drug Safety Inspection Team,Suzhou 215028,China;Department of Rheumatology and Immunology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China;Department of Rheumatology and Immunology,Dushu Lake Hospital Affiliated to Soochow University,Suzhou 215008,China)

机构地区：[1]苏州大学附属第一医院药学部,苏州215031 [2]苏州工业园区食品药品安全稽查大队,苏州215028 [3]苏州大学附属第一医院风湿免疫科,苏州215006 [4]苏州大学附属独墅湖医院风湿免疫科,苏州215008

出　　处：《医药导报》2022年第7期997-1003,共7页Herald of Medicine

基　　金：江苏省研究生科研与实践创新计划项目(SJCX20_1080);苏州市科技局科研项目(SYSD2018232);苏州市卫生青年骨干人才“全国导师制”项目(2021年)。

摘　　要：风湿性疾病泛指可影响骨、骨关节、肌肉、组织并可累及多脏器、多系统的一组疾病。已有的改善病情抗风湿药随着临床应用范围的扩大,其不良反应如感染和癌症发生率增加等问题逐渐显露,且部分患者对已有治疗药物无响应或不能持续应答。近年来生物类改善病情抗风湿药(bDMARDs)和靶向合成改善病情抗风湿药(tsDMARDs)为风湿病的治疗带来了新的希望。该文综述近年来用于治疗风湿病的bDMARDs和tsDMARDs的研究进展,以期为药物治疗风湿病提供参考和依据。Rheumatic diseases generally refer to a group of diseases that can affect bones,bone joints,muscles,and tissues,involving multiple organs and multiple systems.With the expansion of the clinical application of the existing disease-modifying anti-rheumatic drugs,their adverse reactions such as infection and the increase in cancer incidence of have gradually been exposed.And some patients have no response to the existing treatment drugs or cannot continue to respond.In recent years,biological disease-modifying anti-rheumatic drugs(bDMARDs)and targeted synthetic disease-modifying anti-rheumatic drugs(tsDMARDs)had brought new hope for treating of rheumatism.This article reviewed the research progress of bDMARDs and tsDMARDs for the treating rheumatism in recent years,and provided a reference and basis for the treating rheumatism with drugs.

关 键 词：风湿病 生物类改善病情抗风湿药 靶向合成改善病情抗风湿药 

分 类 号：R976[医药卫生—药品] R593[医药卫生—药学]